EA201491453A1 - Неводная жидкая композиция - Google Patents

Неводная жидкая композиция

Info

Publication number
EA201491453A1
EA201491453A1 EA201491453A EA201491453A EA201491453A1 EA 201491453 A1 EA201491453 A1 EA 201491453A1 EA 201491453 A EA201491453 A EA 201491453A EA 201491453 A EA201491453 A EA 201491453A EA 201491453 A1 EA201491453 A1 EA 201491453A1
Authority
EA
Eurasian Patent Office
Prior art keywords
liquid composition
dioleylphosphatidylcholine
tocopherol
mixture
nonwater
Prior art date
Application number
EA201491453A
Other languages
English (en)
Inventor
Кадзухито Ямада
Арто Уртти
Мечтильд Бурместер
Original Assignee
Сантен Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сантен Фармасьютикал Ко., Лтд. filed Critical Сантен Фармасьютикал Ко., Лтд.
Publication of EA201491453A1 publication Critical patent/EA201491453A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Неводная жидкая композиция с растворенным лекарственным средством, включающая лекарственное средство, диолеилфосфатидилхолин, токоферол и органический растворитель, где соотношение концентраций в указанной смеси между указанным диолеилфосфатидилхолином и указанным токоферолом составляет от 75/25 до 25/75, концентрация диолеилфосфатидилхолина в смеси составляет от 15 до 85 вес.% (вес./вес.), концентрация токоферола в смеси составляет от 15 до 85 вес.% (вес./вес.), и фаза неводной жидкой композиции изменяется на неслоистую жидкокристаллическую фазу при контакте с водой, фосфатным буфером, жидкостной средой организма, слезной жидкостью или жидкостью стекловидного тела.
EA201491453A 2012-01-31 2013-01-30 Неводная жидкая композиция EA201491453A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012018062 2012-01-31
PCT/JP2013/051951 WO2013115201A1 (ja) 2012-01-31 2013-01-30 非水性液体組成物

Publications (1)

Publication Number Publication Date
EA201491453A1 true EA201491453A1 (ru) 2014-12-30

Family

ID=48905235

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491453A EA201491453A1 (ru) 2012-01-31 2013-01-30 Неводная жидкая композиция

Country Status (12)

Country Link
US (1) US20150011518A1 (ru)
EP (1) EP2810657B1 (ru)
JP (1) JP2013177372A (ru)
KR (1) KR20150000874A (ru)
CN (1) CN104080478A (ru)
CA (1) CA2861261A1 (ru)
EA (1) EA201491453A1 (ru)
IN (1) IN2014DN06911A (ru)
PH (1) PH12014501689A1 (ru)
SG (2) SG10201606271RA (ru)
TW (1) TW201336526A (ru)
WO (1) WO2013115201A1 (ru)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514878D0 (en) * 1995-07-20 1995-09-20 Danbiosyst Uk Vitamin E as a solubilizer for drugs contained in lipid vehicles
EP0975331A1 (en) * 1997-04-17 2000-02-02 Dumex-Alpharma A/S A novel bioadhesive drug delivery system based on liquid crystals
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
JP4496406B2 (ja) 2003-03-07 2010-07-07 参天製薬株式会社 ４−ピリジルアルキルチオ基を置換基として有する新規化合物
WO2006075124A1 (en) * 2005-01-14 2006-07-20 Camurus Ab Somatostatin analogue formulations
CN1897918A (zh) * 2003-11-17 2007-01-17 阿尔萨公司 包含两亲性分子作为混悬载体的组合物和剂型
JP4626353B2 (ja) 2004-02-17 2011-02-09 参天製薬株式会社 置換又は無置換アミノ基を導入した４−ピリジルアルキルチオ基を有する新規環式化合物
GB0412530D0 (en) * 2004-06-04 2004-07-07 Camurus Ab Formulation
NZ551990A (en) * 2004-06-04 2011-01-28 Camurus Ab Liquid depot formulations
EP1848403B8 (en) * 2005-01-14 2010-05-19 Camurus Ab Topical bioadhesive formulations
KR101245022B1 (ko) * 2005-01-21 2013-03-19 카무러스 에이비 약제학적 지질 조성물
JP4585978B2 (ja) 2005-03-03 2010-11-24 参天製薬株式会社 キノリルアルキルチオ基を有する新規環式化合物
JP4834441B2 (ja) 2005-03-31 2011-12-14 参天製薬株式会社 ピリミジニルアルキルチオ基を有する新規環式化合物
CN101217940B (zh) * 2005-06-06 2013-03-27 卡穆鲁斯公司 Glp-1类似物制剂
JP4825636B2 (ja) 2005-09-14 2011-11-30 参天製薬株式会社 グルココルチコイド受容体結合活性を有する新規１，２−ジヒドロキノリン誘導体
JP5054996B2 (ja) 2006-03-14 2012-10-24 参天製薬株式会社 グルココルチコイド受容体結合活性を有する新規１，２，３，４−テトラヒドロキノキサリン誘導体
KR20090086539A (ko) 2006-11-14 2009-08-13 산텐 세이야꾸 가부시키가이샤 (치환 페닐 또는 치환 복소환) 카르보닐옥시 저급 알킬기와 에스테르 구조를 도입한 페닐기를 치환기로서 갖는 신규 1,2-디히드로퀴놀린 유도체
JP2008266295A (ja) 2007-01-29 2008-11-06 Santen Pharmaceut Co Ltd キナーセ゛阻害活性を有する新規チアシ゛アソ゛ール誘導体
CN101679317B (zh) 2007-05-29 2012-10-31 参天制药株式会社 具有糖皮质激素受体结合活性且具有导入了磺酸酯或磺酰胺结构的苯基作为取代基的1，2，3，4-四氢喹喔啉衍生物
JP2009084274A (ja) 2007-09-13 2009-04-23 Santen Pharmaceut Co Ltd 新規１，３，３−トリメチル−７−フェニル−３，４−ジヒドロ−１ｈ−キノキサリン−２−オン誘導体
CN102471273B (zh) 2009-07-17 2014-07-16 参天制药株式会社 2-[[[2-[(羟基乙酰基)氨基]-4-吡啶基]甲基]硫代]-n-[4-(三氟甲氧基)苯基]-3-吡啶甲酰胺苯磺酸盐、其晶体、其多晶型物以及用于制备其的方法
US8956600B2 (en) * 2009-08-10 2015-02-17 Taiwan Liposome Co. Ltd. Ophthalmic drug delivery system containing phospholipid and cholesterol

Also Published As

Publication number Publication date
CN104080478A (zh) 2014-10-01
US20150011518A1 (en) 2015-01-08
SG10201606271RA (en) 2016-09-29
SG11201404230QA (en) 2014-10-30
EP2810657A4 (en) 2015-07-29
JP2013177372A (ja) 2013-09-09
PH12014501689A1 (en) 2014-10-20
EP2810657B1 (en) 2016-09-21
EP2810657A1 (en) 2014-12-10
WO2013115201A1 (ja) 2013-08-08
IN2014DN06911A (ru) 2015-05-15
CA2861261A1 (en) 2013-08-08
TW201336526A (zh) 2013-09-16
KR20150000874A (ko) 2015-01-05

Similar Documents

Publication Publication Date Title
WO2014066468A8 (en) Stable, low viscosity antibody formulation
EA201590518A1 (ru) Стабильные водные составы адалимумаба
CR20160499A (es) Composiciones estables de yodo no en complejo y métodos de uso
EA201691102A1 (ru) Способ удаления soиз газа при помощи полиольного сложного раствора
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591527A1 (ru) Новые производные пиридина
EA201391298A1 (ru) Неводные концентрированные суспензионные композиции с пониженной вязкостью на основе антител
PE20191714A1 (es) Nanoparticula polimerica de finasterida y minoxidil, proceso de preparacion, suspension acuosa conteniendo la misma, composicion farmaceutica, y su uso
BR112014031310A2 (pt) anticorpos anti-pcsk9, formulações, dosagem e métodos de uso
CL2013003365A1 (es) Formulacion farmaceutica que comprende diacilglicerol y/o tocoferol, fosfatidilcolina, solvente mono-alcoholico organico biocompatible que comprende etanol, solvente polar, y un analogo de somatostatina como principio activo; proceso para prepararla; kit farmaceutico; uso en el tratamiento de acromegalia y canceres, entre otros.
BR112014032956A2 (pt) processos para preparação de 1,2,4-oxadiazois 3,5-dissubstituídos
EA201390412A1 (ru) Стабилизированная композиция такролимуса
MX2018003333A (es) Formulaciones de liberacion controlada.
PE20160549A1 (es) Formulacion liquida estable de etelcalcetida (amg 416)
EA201201453A1 (ru) Неводные лекарственные средства в форме проэмульсии на основе таксанов и способы их приготовления и использования
EA201400822A1 (ru) Производные гетероциклических амидов в качестве антагонистов p2xрецептора
EA201590041A1 (ru) Твердая форма холиновой соли вемурафениба
EA201491063A1 (ru) Применение белков р3 бактериофага в качестве агентов, связывающих амилоид
EA201391555A1 (ru) Составы суспензионного типа для местного применения, содержащие циклический депсипептид
EA201591904A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ N-(2,3-ДИГИДРО-1H-ПИРРОЛО[2,3-b]ПИРИДИН-5-ИЛ)-4-ХИНАЗОЛИНАМИНА И N-(2,3-ДИГИДРО-1H-ИНДОЛ-5-ИЛ)-4-ХИНАЗОЛИНАМИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PERK
GB2534038A (en) Oil-in-water stable, emulsified spacer fluids
PH12015501941A1 (en) Benzo-fused heterocyclic derivatives useful as agonists of gpr120
BR112014000080A8 (pt) dispositivo de reconstituição
EA201291354A1 (ru) Новое применение диатомитовой земли в фармацевтической промышленности
EA201491109A1 (ru) Инвертные буровые растворы с улучшенными реологическими свойствами и способы бурения скважин